Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial entities : Immunitybio inc save search
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
Published: 2024-02-21 (Crawled : 15:00) - biospace.com/
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 1.27%
H: 0.31%
C: -2.3%
first vaccine cancer trial
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
Published: 2024-02-05 (Crawled : 14:30) - immunitybio.com
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: -1.93%
H: 1.35%
C: -0.49%
favorable bladder cancer trial plus study
National Multicenter Trial Opens to Study ImmunityBio’s Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome
Published: 2023-04-25 (Crawled : 13:00) - nantkwest.com
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 0.0%
H: 4.51%
C: -3.69%
cancer trial plus study
ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration
Published: 2023-01-19 (Crawled : 14:20) - nantkwest.com
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: -1.1%
H: 1.11%
C: 0.22%
fda trial presentation asco update cancer pancreatic
Bladder Cancer Clinical Trial Pipeline Insights Featuring 100+ Companies | DelveInsight
Published: 2022-08-23 (Crawled : 16:00) - prnewswire.com
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 0.27%
H: 6.27%
C: 4.0%
URGN | $14.51 0.97% 0.96% 220K
|
Health Technology
|
| O: 0.64%
H: 0.32%
C: -0.63%
TARA | $3.02 -0.98% -0.99% 410K
|
Health Technology
|
| O: -0.38%
H: 3.83%
C: 1.73%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: -0.49%
H: 0.36%
C: -0.33%
companies trial bladder cancer
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published: 2022-06-06 (Crawled : 13:00) - nantkwest.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 0.17%
H: 0.0%
C: 0.0%
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 14.42%
H: 1.88%
C: -4.29%
trial cancer pancreatic bladder
ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-04-28 (Crawled : 13:00) - nantkwest.com
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: -0.13%
H: 3.05%
C: -0.8%
trials
ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer
Published: 2022-04-25 (Crawled : 13:20) - biospace.com/
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: -3.12%
H: 2.86%
C: 0.0%
trial cancer enroll
ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival
Published: 2022-01-18 (Crawled : 00:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -0.4%
H: 0.0%
C: -0.58%
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: -1.27%
H: 0.0%
C: 0.0%
phase 2 trial disease media asco cancer pancreatic
ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing
Published: 2021-12-20 (Crawled : 14:30) - biospace.com/
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 1.53%
H: 1.2%
C: -2.41%
AMRS | $0.05 -21.88% -16.36% 47M
|
Process Industries
|
| O: -2.79%
H: 1.93%
C: -3.72%
als bladder cancer trials trial covid cel clinical trials cancer vaccine phase 3 merge t-cell bladder
ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease
Published: 2021-10-19 (Crawled : 13:15) - nantkwest.com
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 0.9%
H: 2.89%
C: 1.78%
disease bladder cancer cancer trial bladder
National Cancer Institute Selects ImmunityBio’s N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy
Published: 2021-10-04 (Crawled : 13:00) - biospace.com/
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 1.31%
H: 2.69%
C: -1.89%
therapy cancer trial keytruda
ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial
Published: 2021-09-13 (Crawled : 13:00) - nantkwest.com
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 0.81%
H: 3.11%
C: -2.01%
media phase 2 phase 2/3 positive cancer trial response bladder
ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association’s Annual Meeting
Published: 2021-09-01 (Crawled : 13:00) - nantkwest.com
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 0.97%
H: 3.13%
C: 2.7%
presentation phase 2 phase 2/3 results cancer trial trial results bladder
CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C
Published: 2021-08-24 (Crawled : 13:00) - biospace.com/
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 0.28%
H: 4.22%
C: 3.49%
disease phase 2 phase 2/3 results trial
CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022
Published: 2021-07-29 (Crawled : 20:00) - biospace.com/
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 0.61%
H: 1.47%
C: -3.12%
phase 2 results cancer trial pancreatic pancreas
ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19
Published: 2021-07-14 (Crawled : 13:15) - biospace.com/
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 0.77%
H: 1.35%
C: -5.32%
covid phase 1 vaccine trial t-cell authorized africa
ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a ‘Universal Boost’ in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa
Published: 2021-05-25 (Crawled : 13:15) - nantkwest.com
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 2.23%
H: 2.37%
C: -1.93%
covid nasal spray test vaccine trial approval t-cell africa
FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors
Published: 2021-05-17 (Crawled : 13:15) - biospace.com/
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 4.63%
H: 9.4%
C: 4.8%
fda cryo solid tumors trial authorized
ImmunityBio Announces 12-Month Overall Survival Probability of 83% in NCI-Led Phase 1 Study of Multi-Targeted hAd5 Immunotherapy Vaccine in Patients with Advanced Metastatic Prostate Cancer
Published: 2021-03-29 (Crawled : 14:00) - biospace.com/
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 5.86%
H: 2.22%
C: -13.02%
vaccine phase 1 phase 3 phase 2 cancer immunotherapy prostate cancer therapy
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.